Home Alzheimer’s Disease Frontline Therapy of Avelumab Showed Favorable OS Benefit in Japanese Patients With...

Frontline Therapy of Avelumab Showed Favorable OS Benefit in Japanese Patients With Advanced Urothelial Cancer

Avelumab (Bavencio) plus best supportive care (BSC) as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy, according to results of a subgroup analysis presented during the 2021 Genitourinary Cancers Symposium.1

Data from the phase 3 JAVELIN Bladder 100 trial (NCT02603432) showed that the median overall survival (OS) in the Japanese subset was 24.7 months (95% CI, 18.2–not estimable [NE]) with avelumab/BSC (n = 36) compared with 18.7 months (95% CI, 12.8-33.0) with BSC alone (n = 37; unstratified HR, 0.81; 95% CI, 0.41-1.58).

In Japanese patients with PD-L1–positive tumors, the median OS was 18.6 months (9.4–NE) and 19.4 months (95% CI, 11.7-33.0), respectively (HR, 1.00; 95% CI, 0.41-2.41). However, the 95% confidence intervals were wide due to the small number of…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments